Investor Presentaiton
Investor presentation
First three months of 2017
The combined GLP-1 segment accounts for 12% of the
total diabetes care market in North America
GLP-1 value
in bDKK
40
35
30
25
20-
15-
10-
5-
North America GLP-1 market
VictozaⓇ
dulaglutide
other
exenatide
CAGR value¹: 41.8%
Feb
2012
1 CAGR for 5-year period.
Source: IMS Monthly MAT February, 2017 value figures (DKK)
changing
diabetes®
Slide 56
Key observations for VictozaⓇ in the US market
VictozaⓇ value market share within the GLP-1 segment is
54%
Around 81% of commercial and around 89% of Medicare
Part D lives are covered without restrictions
Around 69% of new patients are new to treatment or
from OAD-only regimens
Close to 70% of prescriptions are for the higher dose
1.8 mg (3-pen pack)1
Share of total
diabetes care
market
12%
•
-10%
•
8%
6%
4%
2%
0%
Feb
2017
1 IMS monthly NPA data, February 2017
novo nordiskView entire presentation